Changes in the frequencies of β-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: Activity of ceftazidime-avibactam tested against β-lactamase-producing isolates

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4770-4777

  Castanheira, Mariana ^a   Mendes, Rodrigo E ^a   Jones, Ronald N ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE; CEFTAZIDIME; CEFTRIAXONE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COMPARATIVE STUDY; DNA SEQUENCE; DRUG ACTIVITY; DRUG SCREENING; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENE FREQUENCY; GENETIC STABILITY; GENETIC SUSCEPTIBILITY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEUS MIRABILIS; UNITED STATES; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GENETICS; HOSPITAL; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEMS; CEFTAZIDIME; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84979239762     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00540-16     Document Type: Article

References (26)

1. Ramphal R, Ambrose PG. 2006. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 42(Suppl 4):S164-S172. http://dx.doi.org/10.1086/500663.
2. Bush K. 2008. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 14(Suppl 1):S134-S143.
3. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 58:833-838. http://dx.doi.org/10.1128/AAC.01896-13.
4. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. 2015. Ceftazidime-avibactam activity tested against Enterobacteriaceae from United States hospitals (2011-2013) and characterization of beta-lactamase producing strains. Antimicrob Agents Chemother 59:3509-3517. http://dx.doi.org/10.1128/AAC.00163-15.
5. Canton R, Coque TM. 2006. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 9:466-475. http://dx.doi.org/10.1016/j.mib.2006.08.011.
6. CTX-M among Enterobacteriaceae in U.S. medical centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist 14:211-216.
7. Lewis JS, II, Herrera M, Wickes B, Patterson JE, Jorgensen JH. 2007. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 51:4015-4021. http://dx.doi.org/10.1128/AAC.00576-07.
8. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. 2013. Prevalence of β-lactamase encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 US hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 57:3012-3020. http://dx.doi.org/10.1128/AAC.02252-12.
9. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. 2001. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151-1161. http://dx.doi.org/10.1128/AAC.45.4.1151-1161.2001.
10. CDC. 2015. Tracking CRE infections. CDC, Atlanta, GA. http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html. Accessed December 2015.
11. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Kaiser RM, Castanheira M, Jones RN, Tenover F, Lynfield R. 2013. Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: Report from the 2007-2009 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 76:356-360. http://dx.doi.org/10.1016/j.diagmicrobio.2013.03.032.
14. CDC. 2015. FAQs about choosing and implementing a CRE definition. CDC, Atlanta, GA. http://www.cdc.gov/hai/organisms/cre/definition.html. Accessed December 2015.
15. Allergan. 2015. AVYCAZ prescribing information. Allergan, Irvine, CA. http://www.avycaz.com. Accessed 23 March 2015.
16. EUCAST. January 2015. Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. http://www.eucast.org/clinical-breakpoints/. Accessed January 2015.
17. Schwaber MJ, Carmeli Y. 2014. An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clin Infect Dis 58:697-703. http://dx.doi.org/10.1093/cid/cit795.
18. CDC. 2013. 2012 CRE toolkit - guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). CDC, Atlanta, GA. http://www.cdc.gov/hai/organisms/cre/cre-toolkit/f-level-prevention.html#facility-measures. Accessed December 2015.
19. Winkler ML, Papp-Wallace KM, Bonomo RA. 2015. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. J Antimicrob Chemother 70:2279-2286. http://dx.doi.org/10.1093/jac/dkv094.
20. Winkler ML, Papp-Wallace KM, Taracila MA, Bonomo RA. 2015. Avibactam and inhibitor-resistant SHV beta-lactamases. Antimicrob Agents Chemother 59:3700-3709. http://dx.doi.org/10.1128/AAC.04405-14.
21. Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA. 2015. Variants of the KPC-2 beta-lactamase which are resistant to inhibition by avibactam. Antimicrob Agents Chemother 59:3710-3717. http://dx.doi.org/10.1128/AAC.04406-14.
22. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae Isolate. Antimicrob Agents Chemother 59:6605-6607. http://dx.doi.org/10.1128/AAC.01165-15.
23. Dupont H, Gaillot O, Goetgheluck AS, Plassart C, Emond JP, Lecuru M, Gaillard N, Derdouri S, Lemaire B, Girard de Courtilles M, Cattoir V, Mammeri H. 2016. Molecular characterization of carbapenem-nonsusceptible Enterobacterial isolates collected during a prospective interregional survey in France and susceptibility to the novel ceftazidime-avibactam and aztreonam-avibactam combinations. Antimicrob Agents Chemother 60:215-221. http://dx.doi.org/10.1128/AAC.01559-15.
24. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De PP, Koh TH, Patel R. 2015. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother 59:7842-7846. http://dx.doi.org/10.1128/AAC.02019-15.
25. Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. 2015. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother 59:4239-4248. http://dx.doi.org/10.1128/AAC.00206-15.
26. Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. 2015. In vitro susceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 59:1789-1793. http://dx.doi.org/10.1128/AAC.04191-14.